1st October 2025, Cambridge, UK – Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent requirements of cell therapy research, process development, and GMP manufacturing. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
TEDCO Announces Panel to Discuss the Road to Clinical Trials at 2025 Entrepreneur Expo
COLUMBIA, Md., October 9, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo at The Hotel at the University of Maryland on October 21, 2025.
“The transition from discovery to clinical application represents one of the most complex and pivotal phases of medical research” said Ben Antebi, associate director, Maryland Stem Cell Research Fund (MSCRF). “Navigating this critical pathway properly has a direct impact on shaping the fate of a technology.” [Read more…]
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study
The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of XSTEM. Xintela has previously communicated positive interim results up to 18 months after treatment of knee osteoarthritis patients with three dose levels of XSTEM. The highest dose level, which showed the best results after 18 months, has now shown sustained positive treatment effects two years after XSTEM treatment.
XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. [Read more…]
Maryland Governor Wes Moore to Speak at TEDCO’s 2025 Entrepreneur Expo
Join us in College Park on October 21 during the lunch keynote session
COLUMBIA, Md., Sept. 29, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo. The premier event will take place at The Hotel at the University of Maryland on October 21, 2025. Gov. Moore will be making a special appearance during the lunch keynote session. [Read more…]
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF
SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA.
Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioactive material fields. [Read more…]
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 145
- Next Page »